Janssen Research & Development, LLC - Recruiting 18 years or older. - A Randomized, Open-label, Multicenter, Phase 3 Study of Epoetin Alfa Plus Standard Supportive Care Versus Standard Supportive Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.
Standard supportive care (packed RBC transfusion); epoetin alfa + packed RBC transfusion
Mayo Clinic - Recruiting 18 years or older. - Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With or Without Cyclophosphamide, in Patients With Recurrent or Refractory Multiple Myeloma.
MV-NIS; cyclophosphamide; I-123 prior MV-NIS; I-123 post MV-NIS; Liothyronine
Sanofi - Recruiting N/A or older. - International, Multicenter, Open-label, Treatment-extension Study for Subjects Who Completed a Phase 1 or Phase 2 Parental Study to Continue Receiving Treatment With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen.
National Institutes of Health Clinical Center (CC) - Recruiting 2 years or older. - Evaluation, Treatment and Training Protocol for Patients With Bone Marrow Failure States, Isolated or Multilineage Cytopenias, Metastatic Solid Tumors, or Hematologic Malignancies.
Celgene Corporation - Recruiting 18 years or older. - A Phase 1a/b, Multicenter, Open Label, Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the Dual DNA-PK and TOR Kinase Inhibitor, CC-115, Administered Orally to Subjects With Advanced Solid Tumors, and Hematologic Malignancies..
Mount Sinai School of Medicine - Recruiting 18 years or older. - Multicenter Phase I/II Trial of Ruxolitinib in Combination With Decitabine in Patients With Accelerated Phase Myeloproliferative Neoplasm (MPN) or Post-MPN AML.
AHS Cancer Control Alberta - Recruiting 18 years or older. - A Study to See if a New Type of Imaging Can Help Our Understanding of the Course of Non-small Cell Lung Cancer in Patients Undergoing Treatment With Radiotherapy or Chemoradiotherapy.
NewLink Genetics Corporation - Recruiting 18 years or older. - A Phase III Study of Chemotherapy With or Without Algenpantucel-L (HyperAcuter-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer.
Hpital Edouard Herriot - Recruiting 18 years to 90 years. - TRESTIS: Multicentric Study With a Curative Endoscopic Treatment of Superficial Neoplasia of a Digestive Tract by Endoscopic Submucosal Dissection: Evaluation of a New Water Jet System Injecting Glycerol Mix.
Sanofi - Recruiting 18 years or older. - Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion Every 3 Weeks in Adult Patients With CA6-Positive and Refractory Solid Tumors.
Janssen Research & Development, LLC - Recruiting 18 years to 70 years. - An Open-Label, Multicenter, Pharmacokinetic Study of Trabectedin in Subjects With Advanced Malignancies and Hepatic Dysfunction.
Medica Scientia Innovation Research - Recruiting 18 years or older. - A Phase IIa Prospective, Multicenter, Open and Not Controlled of the Efficacy and Tolerability on the First Line Treatment With Eribulin as a Unic Agent on Patients With HER2 Negative Metastatic Breast Cancer Previously Treated With Taxanes.
Medica Scientia Innovation Research - Recruiting 18 years or older. - Observational, Retrospective and Multicenter Study to Evaluate the Clinical Benefit of Trastuzumab in Combination With Lapatinib in Metastatic Breast Cancer HER2 Positive Patients Who Has Been Previously Treated With Trastuzumab and/or Lapatinib.
Hoffmann-La Roche - Recruiting 18 years to 75 years. - A Multi-center, Single-arm, Pilot Study of 5-FU Based Doublet Chemotherapy Plus Bevacizumab as Neoadjuvant Therapy for Patients With Previously Untreated Unresectable Liver-only Metastases From Colorectal Cancer.
bevacizumab [Avastin]; 5-FU based doublet chemotherapy
Asan Medical Center - Recruiting 20 years or older. - Intraductal Papillary Mucinous Neoplasm (IPMN) With Malignant Change: Prospective Study to Assess Diagnostic Performance of CT and Magnetic Resonance Imaging (MR) According to International Consensus Guidelines 2012.
Stanford University - Recruiting N/A or older. - Pilot Phase I/II Investigational Study to Assess the Efficacy and Safety of Recombinant Hyaluronidase (rHUPH20) in the Treatment of Secondary Lymphedema Resulting From Local Management of Malignancy.
recombinant human hyaluronidase; laboratory biomarker analysis; pharmacological study
Sanofi - Recruiting 18 years or older. - A Phase 1 Dose-escalation Study of the Safety and Pharmacokinetics of a Tablet Formulation of SAR245409 Administered Daily to Patients With Solid Tumors or Lymphoma.
National Guard Health Affairs - Recruiting 18 years or older. - A Randomized, Controlled, Open Label Study of the Efficacy and Safety of the Low Molecular Weight Heparin (LMWH), LovenoxTM (Enoxaparin) Versus HeparinTM (Unfractionated Heparin) for Prevention of Venous Thromboembolism (VTE) in Gynecologic Oncology Patients.
National Institutes of Health Clinical Center (CC) - Recruiting N/A to 17 years. - An Open Label Dose Escalation Safety Study of Convection-Enhanced Delivery of IL13-PE38QQR in Patients With Progressive Pediatric Diffuse Infiltrating Brainstem Glioma and Supratentorial High-Grade Glioma.
National Institutes of Health Clinical Center (CC) - Recruiting 3 years or older. - Definition of the Genotype and Clinical Phenotype of Primary Pigmented Nodular Adrenocortical Disease (PPNAD), Carney Complex, Peutz-Jeghers Syndrome and Related Conditions.
Sanofi - Recruiting 2 years to 18 years. - A Phase 1-2 Dose Finding, Safety and Efficacy Study of Cabazitaxel in Pediatric Patients With Refractory Solid Tumors Including Tumors of the Central Nervous System.
Pfizer - Recruiting 18 years or older. - A Phase 1B Open-Label Three-Arm Multi-Center Study To Assess The Safety And Tolerability Of PF-05212384 (PI3K/MTor Inhibitor) In Combination With Other Anti-Tumor Agents.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Trial of Twice Weekly Induction Followed by Once Weekly IV Velcade (Bortezomib) With Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Following at Least 1 Prior Therapy.
University of Illinois at Chicago - Recruiting 18 years or older. - Phase I Study of Aurora A Kinase Inhibitor (MLN8237) Given in Combination With Selective VEGFR Inhibitor Pazopanib (Votrient) for Therapy in Solid Tumors.
Centre Leon Berard - Recruiting 18 years or older. - A Phase II, Multicenter Trial Aiming to Evaluate the Clinical Interest of a Monotherapy With BKM120 , a PI3K Inhibitor in Patient With Metastatic Head and Neck Cancer Recurrent or Progressive Under Platin and Cetuximab-based Chemotherapy.
Thomas Jefferson University - Recruiting 18 years or older. - A Two Step Approach to Haploidentical Hematopoietic Stem Cell Transplantation for Patients in Remission From HLA Partially-Matched Related Donors-Effect of Maternal Donors on Outcomes.
National Cancer Institute (NCI) - Recruiting 3 years to 21 years. - A Randomized Phase II/III Study of Vorinostat (IND# 71976) and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab (IND# 7921) and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas.
Southwest Oncology Group - Recruiting N/A or older. - S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment.
University Hospitals, Leicester - Recruiting 18 years or older. - Phase II Trial of Palliative Epirubicin, Oxaliplatin & Capecitabine (EOX) Chemotherapy Combined With Omega-3 Fish Oil Infusion (Omegaven) in Patients With Oesophagogastric Carcinoma.
Hospital Universitari de Bellvitge - Recruiting 18 years to 74 years. - Prospective Multicenter Randomized Controlled Trial Comparing Postoperative Complications and Quality of Life in Low Rectal Cancer Surgery Between Coloanal Anastomosis and Lateral Ileostomy Versus Two-Stage Turnbull-Cutait Coloanal Anastomosis.
Hand-sewn coloanal anastomosis; Two staged Turnbull-Cutait procedure; Ultralow anterior rectal resection with total mesorectal excision
University of Maryland - Recruiting 18 years or older. - GCC 0901- A Phase II Study of Letrozole in Combination With Lapatinib Followed by an Addition of Everolimus in Postmenopausal Women With Advanced Endocrine Resistant Breast Cancer.
AHS Cancer Control Alberta - Recruiting 18 years or older. - A Multicentre, Open-label Phase II Study of Irinotecan, Capecitabine(Xeloda), and Oxaliplatin (IXO) as First Line Treatment in Patients With Metastatic Gastric or Gastroesophageal (GEJ) Adenocarcinoma..
Catharina Ziekenhuis Eindhoven - Recruiting 18 years or older. - Phase II Multicentre Open Label Study Evaluating the Efficacy and Safety of Liposomal Doxorubicin, Trastuzumab, Docetaxel as First-line Treatment of Patients With HER2 Positive Metastatic Breast Cancer.
Non pegylated liposomal doxorubicin, trastuzumab, docetaxel
Ludwig Institute for Cancer Research - Recruiting N/A or older. - Cohort Study of Increasing Doses of Yttrium-90 Conjugated to Chimeric Monoclonal Antibody cG250 (90Y-DOTA-cG250) in Patients With Advanced Renal Cancer.
Korean Association for the Study of Intestinal Diseases - Recruiting 45 years to 75 years. - Prospective Randomized Controlled Trial of Cap-Assisted ChromoEndoscopy(CapACE) Versus Conventional Colonoscopy(CC) for the Detection and 3-year Recurrence Rate of Colorectal Neoplasia.
Japan Clinical Oncology Group - Recruiting 20 years to 75 years. - Randomized Phase III Trial of Surgery Plus Neoadjuvant TS-1 and Cisplatin Compared With Surgery Alone for Type 4 and Large Type 3 Gastric Cancer: Japan Clinical Oncology Group Study (JCOG 0501).
Gastrectomy with more than D2 dissection; Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
Japan Clinical Oncology Group - Recruiting 20 years to 79 years. - Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504).
Whole brain radiation therapy arm; Salvage stereotactic radiosurgery arm
University Health Network, Toronto - Recruiting 18 years to 75 years. - Cognitive Function and Fatigue in Cancer Patients After Chemotherapy: A Longitudinal Controlled Study in Patients With Colorectal Cancer.